{"id":"c713169b927e","type":"article","url":"https://hartvaat.nl/2026/02/13/bcma-gerichte-t-cel-engagertherapie-bij-refractaire-hla-sensitisatie/","title":"BCMA-gerichte T-cel-engagertherapie bij refractaire HLA-sensitisatie","title_en":"B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00092-X/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00092-X/fulltext","authors":["Juliette Leon","Olivier Aubert","Magali Devriese","Florence Alameda","Soëli Charbonnier","Jacques Fourgeaud","Tifanie Blein","Thu Ngan Nguyen","Antoine Troger","Stéphanie Chhun","Marie Roelens","Cédric Usureau","Camille Gons","Camille Roger","Carole Burger","Marie-Bénédicte Le Stang","Camille Cotteret","Marc-Olivier Timsit","Simon Fillatreau","Marion Rabant","Jean-Luc Taupin","Alexis Talbot","Felipe Suarez","Dany Anglicheau","Julien Zuber"],"significance":6,"published":"2026-02-13","source_date":"2026-02-13","image":"","kennis":[],"congress":"","summary_en":"This study tested B-cell maturation antigen-targeted T-cell engager therapy combined with B-cell depletion for refractory anti-HLA antibodies in transplant candidates, exploring novel immunotherapy to overcome sensitization barriers.","created":"2026-07-03T10:25:22Z","updated":"2026-07-03T13:24:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Voorgevormde anti-HLA-antilichamen vormen een grote barrière voor succesvolle niertransplantatie. Ondanks vooruitgang in desensitisatie zijn huidige therapieën beperkt effectief. Deze studie onderzocht BCMA-gerichte T-cel-engagertherapie gecombineerd met B-celdepletie.","abstract_original":"Preformed, high-titer anti-human leukocyte antigen (HLA) antibodies remain a major barrier to successful kidney transplantation, increasing the risk of early graft loss and prolonged time on dialysis. Despite advances in desensitization, current therapies are largely ineffective for patients with extremely high antibody levels."}